Results 71 to 80 of about 80,577 (303)

Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm [PDF]

Janus kinase inhibitors (JAKi) are effective treatments for rheumatoid arthritis (RA), but growing evidence raises cardiovascular (CV) safety concerns. Given the elevated baseline CV risk in RA, appropriate risk stratification is essential.
Mario Cascone, Francesco Caso, Nicoletta Bertolini, Alfonso Oriente, Luisa Costa, Rosario Peluso, Francesca Foglia, Marco Tasso, Antonio Del Puente   +8 more
core   +1 more source

Janus Kinase-Signal Transducer and Activator of Transcription in target therapy of cancer [PDF]

, 2019
Department of Biochemistry, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of MoldovaBackground: Janus kinase-signal transducer and activator of transcription (JAK-STAT) is a family of intracellular, nonreceptor ...
Shoev, Lior, Simionica, Eugeniu
core   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis

Nature Communications
Tofacitinib, a pan–Janus kinase inhibitor, and the Janus kinase 1–preferential inhibitors Upadacitinib and Filgotinib are approved for the treatment of ulcerative colitis, yet their molecular mechanisms of action remain incompletely understood.
Beibei Liu, Marianne R. Spalinger, Annalisa Invernizzi, Eike Gerdes, Babett Steglich, Marlene Schwarzfischer, Andres Machicote, Penelope Pelczar, Doris Pöhlmann, Mikolaj Nawrocki, Marius Böttcher, Ayob Aleko, Lis Noelia Velasquez, Sandra Wende, Franziska Stallbaum, Justus Neuendorff, Saskia Grosshauser, Franziska Muscate, Gemma Douilhet, Laura Garcia Perez, Morsal Sabihi, Katharina Möller, Florian Viehweger, Jan P. Sutter, Christoph Kilian, Yogesh Kumar, Thorben Fründt, Guido Sauter, Thomas Rösch, Nicola Gagliani, Amedeo Caflisch, Michael Scharl, Samuel Huber   +32 more
doaj   +1 more source

Janus kinase 3: the controller and the controlled [PDF]

Acta Biochimica et Biophysica Sinica, 2012
Janus kinase (JAK)-signal transducer and activators of transcription (STAT) signaling pathways play crucial roles in lymphopoiesis. In particular, JAK3 has unique functions in the lymphoid system such that JAK3 ablation results in phenotypes resembling severe combined immunodeficiency syndrome.
Wei, Wu, Xiao-Hong, Sun
openaire   +2 more sources

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare [PDF]

, 2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma ...
William Damsky (6844733)
core   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan.

PLoS ONE
Anemia is associated with increased morbidity, mortality, healthcare resource utilization, and costs in myelofibrosis. This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to ...
Yusuke Yasutomi, Masashi Takano, Yi-Chen Chen, Chi-Chang Chen, Seok-Won Kim, Catherine McGuiness, Alex Slowley, Keita Kirito   +7 more
doaj   +1 more source

Role of janus kinase inhibitors in the treatment of alopecia areata [PDF]

, 2018
Korn Triyangkulsri, Poonkiat Suchonwanit Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract: Alopecia areata (AA) is a common hair loss disorder worldwide with ...
Suchonwanit P, Triyangkulsri K
core  

Janus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literature [PDF]

, 2019
Cytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors promises the start of a revolution in the treatment of several chronic diseases.
Morrissey, Hana, NOURI, ABDULLA KHALID, Askari, Ayman, Ball, Patrick, BALL, PATRICK A.   +4 more
core   +1 more source